[go: up one dir, main page]

PL3126354T3 - Fluorowcowane chinazolino-THF-aminy jako inhibitory PDE1 - Google Patents

Fluorowcowane chinazolino-THF-aminy jako inhibitory PDE1

Info

Publication number
PL3126354T3
PL3126354T3 PL15713186T PL15713186T PL3126354T3 PL 3126354 T3 PL3126354 T3 PL 3126354T3 PL 15713186 T PL15713186 T PL 15713186T PL 15713186 T PL15713186 T PL 15713186T PL 3126354 T3 PL3126354 T3 PL 3126354T3
Authority
PL
Poland
Prior art keywords
thf
amines
pde1 inhibitors
quinazolin
halogenated
Prior art date
Application number
PL15713186T
Other languages
English (en)
Inventor
Jan Kehler
Lars Kyhn Rasmussen
Morten LANGGÅRD
Original Assignee
H. Lundbeck A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H. Lundbeck A/S filed Critical H. Lundbeck A/S
Publication of PL3126354T3 publication Critical patent/PL3126354T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/044Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/044Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
PL15713186T 2014-04-04 2015-03-27 Fluorowcowane chinazolino-THF-aminy jako inhibitory PDE1 PL3126354T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA201400194 2014-04-04
PCT/EP2015/056713 WO2015150254A1 (en) 2014-04-04 2015-03-27 Halogenated quinazolin-thf-amines as pde1 inhibitors
EP15713186.3A EP3126354B1 (en) 2014-04-04 2015-03-27 Halogenated quinazolin-thf-amines as pde1 inhibitors

Publications (1)

Publication Number Publication Date
PL3126354T3 true PL3126354T3 (pl) 2020-06-15

Family

ID=52779655

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15713186T PL3126354T3 (pl) 2014-04-04 2015-03-27 Fluorowcowane chinazolino-THF-aminy jako inhibitory PDE1

Country Status (39)

Country Link
US (2) US10005764B2 (pl)
EP (1) EP3126354B1 (pl)
JP (1) JP6554116B2 (pl)
KR (1) KR20160138084A (pl)
CN (2) CN109999039A (pl)
AP (1) AP2016009521A0 (pl)
AR (1) AR101155A1 (pl)
AU (1) AU2015239696B2 (pl)
CA (1) CA2943011A1 (pl)
CL (1) CL2016002515A1 (pl)
CR (1) CR20160463A (pl)
CY (1) CY1122784T1 (pl)
DK (1) DK3126354T3 (pl)
DO (1) DOP2016000263A (pl)
EA (1) EA032579B1 (pl)
EC (1) ECSP16082599A (pl)
ES (1) ES2776359T3 (pl)
GE (1) GEP20186920B (pl)
GT (1) GT201600213A (pl)
HR (1) HRP20200369T1 (pl)
IL (1) IL248078B (pl)
JO (1) JO3628B1 (pl)
LT (1) LT3126354T (pl)
MA (1) MA39837B1 (pl)
MX (1) MX364519B (pl)
PE (1) PE20161380A1 (pl)
PH (1) PH12016501938A1 (pl)
PL (1) PL3126354T3 (pl)
PT (1) PT3126354T (pl)
RS (1) RS60017B1 (pl)
RU (1) RU2692808C2 (pl)
SG (1) SG11201608190YA (pl)
SI (1) SI3126354T1 (pl)
SM (1) SMT202000132T1 (pl)
SV (1) SV2016005297A (pl)
TW (1) TWI664178B (pl)
UA (1) UA119166C2 (pl)
WO (1) WO2015150254A1 (pl)
ZA (1) ZA201606566B (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10005764B2 (en) 2014-04-04 2018-06-26 H. Lundbeck A/S Halogenated quinazolin-THF-amines as PDE1 inhibitors
CN110337437B (zh) 2016-12-28 2023-02-03 达特神经科学有限公司 作为pde2抑制剂的取代的吡唑并嘧啶酮化合物
MX2020005447A (es) * 2017-11-27 2020-12-03 Dart Neuroscience Llc Compuestos de furanopirimidina sustituida como inhibidores de pde1.
WO2019227004A1 (en) 2018-05-25 2019-11-28 Intra-Cellular Therapies, Inc. Organic compounds
CN117105809B (zh) * 2023-10-20 2024-05-03 中国农业大学 一种苯甲酰苯胺化合物及其制备方法和应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10042058A1 (de) * 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
GB0229281D0 (en) * 2002-12-16 2003-01-22 Novartis Ag Organic compounds
CN1784391B (zh) * 2003-03-03 2010-06-09 沃泰克斯药物股份有限公司 可用作离子通道调控剂的喹唑啉
GB0327319D0 (en) * 2003-11-24 2003-12-24 Pfizer Ltd Novel pharmaceuticals
US20060019975A1 (en) * 2004-07-23 2006-01-26 Pfizer Inc Novel piperidyl derivatives of quinazoline and isoquinoline
US20060183763A1 (en) * 2004-12-31 2006-08-17 Pfizer Inc Novel pyrrolidyl derivatives of heteroaromatic compounds
JP2009527542A (ja) * 2006-02-23 2009-07-30 ファイザー・プロダクツ・インク Pde10阻害薬としての置換キナゾリン
US20070265258A1 (en) * 2006-03-06 2007-11-15 Ruiping Liu Quinazoline derivatives as phosphodiesterase 10 inhibitors
CN102574817A (zh) * 2009-09-24 2012-07-11 巴斯夫欧洲公司 用于抵抗无脊椎动物害虫的氨基喹唑啉化合物
US20130116241A1 (en) * 2011-11-09 2013-05-09 Abbvie Inc. Novel inhibitor compounds of phosphodiesterase type 10a
TW201609713A (zh) 2013-12-19 2016-03-16 H 朗德貝克公司 作爲pde1抑制劑之喹唑啉-thf-胺
TW201611834A (en) 2014-02-07 2016-04-01 Lundbeck & Co As H Hexahydrofuropyrroles as PDE1 inhibitors
CN106458984A (zh) 2014-04-04 2017-02-22 豪夫迈·罗氏有限公司 作为大麻素受体激动剂的5,6‑双取代的吡啶‑2‑甲酰胺
AP2016009514A0 (en) 2014-04-04 2016-10-31 Pfizer Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors
AR099937A1 (es) 2014-04-04 2016-08-31 Sanofi Sa Compuestos de isoindolinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados
US10005764B2 (en) 2014-04-04 2018-06-26 H. Lundbeck A/S Halogenated quinazolin-THF-amines as PDE1 inhibitors
TW201625605A (zh) 2014-04-04 2016-07-16 賽諾菲公司 用於治療糖尿病、肥胖、血脂異常及相關病症之作為gpr119調節劑的經取代之稠合雜環類
PE20161370A1 (es) 2014-04-04 2016-12-17 Hoffmann La Roche Nuevos derivados de piridina utiles como antagonistas de cb2

Also Published As

Publication number Publication date
MX2016012955A (es) 2016-12-07
US20170022186A1 (en) 2017-01-26
EP3126354A1 (en) 2017-02-08
JP6554116B2 (ja) 2019-07-31
RU2692808C2 (ru) 2019-06-27
CL2016002515A1 (es) 2016-12-16
AP2016009521A0 (en) 2016-10-31
UA119166C2 (uk) 2019-05-10
SV2016005297A (es) 2016-11-30
EP3126354B1 (en) 2020-01-22
EA032579B1 (ru) 2019-06-28
EA201691773A1 (ru) 2017-01-30
TWI664178B (zh) 2019-07-01
JO3628B1 (ar) 2020-08-27
GT201600213A (es) 2019-07-29
DK3126354T3 (da) 2020-03-09
AR101155A1 (es) 2016-11-30
WO2015150254A1 (en) 2015-10-08
CN109999039A (zh) 2019-07-12
US20190144434A1 (en) 2019-05-16
RS60017B1 (sr) 2020-04-30
ECSP16082599A (es) 2017-02-24
CR20160463A (es) 2017-03-06
RU2016138743A3 (pl) 2019-01-15
US10005764B2 (en) 2018-06-26
IL248078B (en) 2018-11-29
PE20161380A1 (es) 2017-01-15
MX364519B (es) 2019-04-30
PT3126354T (pt) 2020-03-17
LT3126354T (lt) 2020-03-25
PH12016501938A1 (en) 2017-02-06
CN106132953A (zh) 2016-11-16
CN106132953B (zh) 2019-03-22
CA2943011A1 (en) 2015-10-08
AU2015239696B2 (en) 2019-10-24
RU2016138743A (ru) 2018-05-07
TW201620901A (zh) 2016-06-16
US10526319B2 (en) 2020-01-07
GEP20186920B (en) 2018-11-12
KR20160138084A (ko) 2016-12-02
MA39837B1 (fr) 2020-05-29
ZA201606566B (en) 2017-11-29
JP2017509680A (ja) 2017-04-06
SMT202000132T1 (it) 2020-05-08
ES2776359T3 (es) 2020-07-30
AU2015239696A1 (en) 2016-10-06
DOP2016000263A (es) 2016-11-30
SI3126354T1 (sl) 2020-04-30
SG11201608190YA (en) 2016-10-28
HRP20200369T1 (hr) 2020-08-07
CY1122784T1 (el) 2021-05-05

Similar Documents

Publication Publication Date Title
IL287113A (en) smyd inhibitors
IL251420A0 (en) Triazolopyrazinones as pde1 inhibitors
GB2531928B (en) Image-stitching for dimensioning
IL246785A0 (en) Benzimidazole-2-amines as midh1 inhibitors
GB201817189D0 (en) Image-stitching for dimensioning
IL255316B (en) Imidazo- pyrazinones as pde1 inhibitors
IL248895A0 (en) Phosphatidylinositol 3-kinase inhibitors
IL248078B (en) Halogenated thf quinazoline amines as pde1 inhibitors
IL252866A0 (en) History of imidazopyridazine as pi3kbeta inhibitors
IL246718A0 (en) Hexahydrofuropyrroles as pde1 inhibitors
IL249075B (en) agent for fluoroalkylation
SG11201607674SA (en) Retinoic-acid-producing agent
AU5592P (en) Lanmichigan Mandevilla boliviensis x sanderi
GB201418154D0 (en) Inhibitors
GB201419294D0 (en) Energy-liberating transformation
GB201407865D0 (en) Nucleases